The experience of flow cytometry for specific antibody against cisplatin‐treated red blood cells: A case report. Issue 4 (2nd February 2023)

• Record Type: Journal Article
• Authors: Suzuki, Kazutaka; Nagaharu, Keiki; Maruyama, Mitsuko; Matsumoto, Takeshi; Ohishi, Kohshi; Tawara, Isao
• Is Part Of: Transfusion. Volume 63:Issue 4(2023)
• Page Start: 867
• Page End: 871
• Publication Date: 2023-02-02
• Subjects: AIHA/drug‐induced IHA -- hematology—red cells -- RBC transfusion; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.17267
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract: Background: Cisplatin‐associated hemolysis is a rare but important adverse effect. Nonimmunological protein adsorption (NIPA) due to erythrocyte membrane modification has been reported as the leading cause of cisplatin‐associated hemolysis. However, limited data exist on cisplatin‐associated immunological hemolysis because of a lack of an established diagnostic method. Here, we used flow cytometry (FCM) to diagnose a patient with cisplatin‐associated immunological hemolysis. Study Design and Methods: A 55‐year‐old woman with uterocervical cancer was treated with weekly cisplatin monotherapy (40 mg/m 2 ). She had no previous transfusion and medication history, nor any significant family history. On the 26th day after cisplatin administration, severe hemolysis was noted. Her red blood cells (RBCs) and sera were evaluated by direct antiglobulin test (DAT) and indirect antiglobulin test (IAT), respectively. To explore immunological reactions for cisplatin‐treated RBCs, we attempted FCM using cisplatin‐treated and ‐untreated RBCs. After incubating conditioned RBCs with the patient's serum or healthy donor serum, we evaluated their fluorescent intensity by fluorescein isothiocyanate (FITC)‐conjugated anti‐human immunoglobulin (Ig) G antibodies. Results: The patient's DAT was positive, and an IAT using her plasma was positive for cisplatin‐treated RBCs. FCM using cisplatin‐treated RBCs revealed that the patient's serum had higher FITC intensity than the donor's serum, indicating the existence of cisplatin‐treated RBC‐specific IgGs in patient's serum. Conclusion: Here, we report a rare case of a patient with hemolysis diagnosed using FCM to identify specific antibodies against cisplatin‐treated RBCs. NIPA and immunological mechanisms may contribute to hemolysis onset during cisplatin treatment.